Conexeu Sciences (CNXU) closed a private placement of approximately $5 million, with some management and director subscriptions awaiting stockholder approval. The financing comprises 1,666,667 units at $3.00 each, each containing one common share and one warrant exercisable at $3.00 per share for 24 months from issuance. Certain Canadian subscribers received special warrants instead. Management and director subscriptions of $250,000 remain in escrow pending stockholder approval; without approval, those funds will be returned and the related securities will not be issued.
Conexeu intends to fund manufacturing scale-up, regulatory testing and preclinical work supporting its planned first-quarter 2027 FDA 510(k) submission for Ten Minute Tissue, its wound care device candidate. Multiple scaled-up CXU batches met predefined company specifications in its October 6 update. No placement agent was engaged or commissions paid.
Conexeu Sciences (CNXU) advanced manufacturing and testing for Ten Minute Tissue™, targeting an FDA submission in the first quarter of 2027. Multiple scaled-up batches of CXU™ material met predefined company specifications for material characteristics and product performance. Conexeu is expanding production of representative test samples and developing processes, supplier relationships and production capabilities for larger-volume manufacturing, subject to FDA clearance.
The company says its planned 510(k) submission, seeking clearance through comparison with a legally marketed device, remains on track. Non-human wound studies, including pilots, and material compatibility, chemical, performance, sterilization, packaging and storage-stability work are underway. FDA advisory feedback is being incorporated into development planning. None of the cited studies evaluated CXU™ in the specific wound-care applications described; supporting evidence is being developed.
Conexeu Sciences (Nasdaq: CNXU), a preclinical-stage biotechnology company developing the CXU™ regenerative tissue platform, announced its participation in three investor and industry conferences in September and October 2026. Management will present and hold meetings at the Nasdaq / LD Micro Summit Series on September 9, 2026 in San Francisco; the H.C. Wainwright 28th Annual Global Investment Conference on September 14–16, 2026 in New York; and H.C. Wainwright’s 2026 Biotech on Tap event on October 1–3, 2026 in Munich. These events will feature CEO Miles Harrison and senior executives engaging with investors and industry stakeholders as Conexeu advances its predicate-based U.S. regulatory strategy toward an anticipated 510(k) submission in early 2027 for its Ten-Minute Tissue™ ECM device.
Conexeu Sciences (Nasdaq: CNXU), a preclinical-stage regenerative tissue platform company, highlights the emergence of a new medical aesthetics category focused on regenerative soft-tissue restoration, centered on the extracellular matrix (ECM). Independent research cited by Conexeu sizes the bioregenerative aesthetics segment at about $1.6 billion in 2025 with projected annual growth above 11%, within a broader regenerative aesthetics market estimated at $15.6 billion.
Conexeu’s patented CXU™ ECM platform is designed as a multi-component collagen-ECM scaffold and underpins its lead device candidate, Ten-Minute Tissue™, a thermosensitive ECM material that gels in situ at body temperature in about ten minutes. The company recently completed the 12‑month P.R.O.O.F. preclinical phase, which met predefined objectives in small-volume facial and approximately 200cc-equivalent large-volume subcutaneous tissue models, while noting these volumes do not establish appropriate or safe human dosing. Conexeu holds a multi-jurisdictional patent estate spanning more than 40 jurisdictions and is pursuing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.
Conexeu (Nasdaq: CNXU) announced that Chief Medical Officer Dr. Brian Pilcher will give an industry presentation at the 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium, held August 14–16, 2026. His August 15 talk, “Beyond Filling: An Extracellular Matrix Blueprint for Tissue Regeneration,” will focus on the role of the extracellular matrix (ECM) in tissue regeneration and regenerative aesthetics.
The presentation aligns with Conexeu’s preclinical CXU™ ECM platform and its lead thermosensitive device candidate, Ten-Minute Tissue™, which is designed to support soft-tissue restoration and is supported by multiple peer‑reviewed preclinical studies.
Conexeu Sciences (Nasdaq: CNXU) outlined its strategy to enter large-volume injectable aesthetics with its investigational tissue-restoration platform CXU™, targeting currently unserved needs such as breast, hip, and buttock volume restoration at scales existing fillers do not address.
The company has completed its 12‑month P.R.O.O.F. preclinical program (Performance and Regeneration Outcomes of Flowable Collagen), evaluating CXU™ in a large-volume model and on injectable mechanical performance. According to Conexeu, CXU™ is a thermosensitive, flowable collagen scaffold designed to flow through fine needles, conform in three dimensions, and set at body temperature to support tissue regeneration. The company is pursuing a predicate-based regulatory pathway and is targeting a 510(k) submission for its lead candidate in the first quarter of 2027, subject to required testing, manufacturing, and documentation. Conexeu links its opportunity to growing breast and buttock augmentation markets and GLP‑1-driven demand for aesthetic volume restoration.
Conexeu Sciences (Nasdaq: CNXU) opened a new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, Canada. The company marked the milestone with a ribbon-cutting ceremony on June 23.
The lab will focus on the CXU™ regenerative tissue platform and B.R.E.A.S.T.™, a 3D‑bioprinted breast matrix for post‑mastectomy tissue regeneration.
Conexeu (Nasdaq:CNXU) expanded its leadership following its Nasdaq listing, increasing the Board from six to nine directors and updating committee roles.
The company appointed Ana Bastiani-Posner, April Burke, and Andrew Costa to the Board, named Co-Founder David Bogart as Chief Commercial Officer, and added aesthetics expert Melinda Farina to its advisory board, supporting commercialization of its CXU™ platform and preclinical B.R.E.A.S.T.™ breast matrix.
Conexeu Sciences (Nasdaq: CNXU) reported progress in manufacturing scale up and standardized formulation for its lead CXU™ wound care device, working with a CDMO to generate materials for regulatory testing.
The company targets a 510(k) FDA submission in Q1 2027, supported by ongoing manufacturing, packaging, sterilization, and documentation activities, informed by FDA Q-Submission feedback.
Conexeu Sciences (Nasdaq: CNXU), a biotechnology company focused on tissue regeneration, will ring the Nasdaq Closing Bell on June 10, 2026, celebrating its recent public listing and trading under ticker CNXU.
The event highlights its BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE™ B.R.E.A.S.T.™ program and CXU™ platform.